Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study.
Luiting HB, Remmers S, Valdagni R, Boevé ER, Staerman F, Rueb J, Somford DM, Pickles T, Rannikko A, Roobol MJ; PRIAS consortium. Luiting HB, et al. Among authors: staerman f. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1048-1054. doi: 10.1038/s41391-021-00343-2. Epub 2021 Apr 8. Prostate Cancer Prostatic Dis. 2021. PMID: 33833378 Free PMC article.
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ. Bul M, et al. Among authors: staerman f. Eur Urol. 2013 Apr;63(4):597-603. doi: 10.1016/j.eururo.2012.11.005. Epub 2012 Nov 12. Eur Urol. 2013. PMID: 23159452 Clinical Trial.
A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
Luiting HB, Remmers S, Boevé ER, Valdagni R, Chiu PK, Semjonow A, Berge V, Tully KH, Rannikko AS, Staerman F, Roobol MJ. Luiting HB, et al. Among authors: staerman f. Eur Urol Oncol. 2022 Dec;5(6):651-658. doi: 10.1016/j.euo.2022.03.007. Epub 2022 Apr 15. Eur Urol Oncol. 2022. PMID: 35437217 Free article.
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH. van den Bergh RC, et al. Among authors: staerman f. BJU Int. 2010 Apr;105(7):956-62. doi: 10.1111/j.1464-410X.2009.08887.x. Epub 2009 Oct 8. BJU Int. 2010. PMID: 19817747
Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy.
Ploussard G, Staerman F, Pierrevelcin J, Saad R, Beauval JB, Roupret M, Audenet F, Peyromaure M, Delongchamps NB, Vincendeau S, Fardoun T, Rigaud J, Villers A, Bastide C, Soulie M, Salomon L; Committee of Cancerology of the Association of French Urology. Ploussard G, et al. Among authors: staerman f. J Urol. 2013 Nov;190(5):1750-6. doi: 10.1016/j.juro.2013.04.073. Epub 2013 Apr 30. J Urol. 2013. PMID: 23643600
Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study.
Ploussard G, Staerman F, Pierrevelcin J, Larue S, Villers A, Ouzzane A, Bastide C, Gaschignard N, Buge F, Pfister C, Bonniol R, Rebillard X, Fadli S, Mottet N, Saint F, Saad R, Beauval JB, Roupret M, Audenet F, Peyromaure M, Delongchamps NB, Vincendeau S, Fardoun T, Rigaud J, Soulie M, Salomon L; Committee of Cancerology (CCAFU) of the Association of French Urology (AFU). Ploussard G, et al. Among authors: staerman f. World J Urol. 2014 Oct;32(5):1331-8. doi: 10.1007/s00345-013-1214-0. Epub 2013 Nov 24. World J Urol. 2014. PMID: 24270970
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
Neuzillet Y, Tillou X, Mathieu R, Long JA, Gigante M, Paparel P, Poissonnier L, Baumert H, Escudier B, Lang H, Rioux-Leclercq N, Bigot P, Bernhard JC, Albiges L, Bastien L, Petit J, Saint F, Bruyere F, Boutin JM, Brichart N, Karam G, Branchereau J, Ferriere JM, Wallerand H, Barbet S, Elkentaoui H, Hubert J, Feuillu B, Theveniaud PE, Villers A, Zini L, Descazeaux A, Roupret M, Barrou B, Fehri K, Lebret T, Tostain J, Terrier JE, Terrier N, Martin L, Dugardin F, Galliot I, Staerman F, Azemar MD, Irani J, Tisserand B, Timsit MO, Sallusto F, Rischmann P, Guy L, Valeri A, Deruelle C, Azzouzi AR, Chautard D, Mejean A, Salomon L, Rigaud J, Pfister C, Soulié M, Kleinclauss F, Badet L, Patard JJ; Comité de Transplantation de l'Association Française d'Urologie; Comité de Cancérologie de l'Association Française d'Urologie. Neuzillet Y, et al. Among authors: staerman f. Eur Urol. 2011 Aug;60(2):366-73. doi: 10.1016/j.eururo.2011.02.035. Epub 2011 Mar 2. Eur Urol. 2011. PMID: 21377780
111 results